A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00323635|
Recruitment Status : Terminated (New department chairman instructed PI to discontinue study.)
First Posted : May 9, 2006
Results First Posted : December 4, 2014
Last Update Posted : March 29, 2018
This study is being done to compare frequency of urination during the night when women take tolterodine tablets vs. when they take placebo tablets.
We will also measure whether between these two treatment conditions there are any differences in women's sleep, mood and performance on cognitive tests.
|Condition or disease||Intervention/treatment||Phase|
|Urinary Incontinence||Drug: tolterodine||Phase 4|
From midlife onwards, about half of women complain of poor sleep quality. One possible reason might be an increased frequency of need to urinate during the night. Women feel more frequent urges to urinate when structures that support the bladder become more lax. Tolterodine is a drug that can raise the threshold for volume of urine that accumulates in the bladder before the urge to urinate arises.
Many factors determine how people say they sleep, such as their sleep as recorded by sleep-measuring instruments, how closely they notice their night's sleep, whether they are generally prone to make positive or negative judgments or to have a lot or a few body symptoms.
In this study, women between ages 45 to 65 who are past the menopause and who are frequently bothered by the need to urinate during the night will take either tolterodine or placebo tablets for 8 weeks. During the last week they will record the hours they slept and the quality of their sleep each morning. They will wear a device on their wrist through the week that continuously records whether they are asleep or awake. During three nights of the week they will record the volume of urine whenever they urinate. At the end of the week they will complete questionnaires about their mood and take some computerized tests that measure their alertness. Thereafter they will repeat these procedures, taking the kind of tablets they did not take during the first 8-week treatment period.
We will compare the frequency of urination, sleep, mood as adjusted for the tendency to make positive or negative judgments and daytime attention level to find if any of these differ between the two treatment periods, and to explain differences between any differences that may be found.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||19 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Parallel, Double-blind Comparison of Tolterodine vs. Placebo Treatments for Nocturia in Postmenopausal Women.|
|Study Start Date :||April 2006|
|Actual Primary Completion Date :||January 2010|
|Actual Study Completion Date :||January 2011|
Tolterodine 4 mg q.d. X 8 weeks
tablet, 4 mg, daily, 1 month
Other Name: Detrol
Placebo Comparator: Placebo
A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine
tablet, 4 mg, daily, 1 month
Other Name: Detrol
- Nocturnal Urinary Frequency, Recorded on an Event/Symptom Chart; [ Time Frame: 2 months ]Subjects note: 1. Number of nocturnal and diurnal voids; 2) level of urgency for 7 days, graded 1 to 4, beginning after the first void on the Friday morning of week 7 and week 13 of their participation; 3) Number of incontinence episodes; 4) Relationship of incontinence to urge or stress (4 grade scale); 4) Whether she used any pads.
- Urgency [ Time Frame: Beginning after the first void on the Friday morning of week 7 and week 13 of their participation; ]Level of urgency for 7 days, graded 1 to 4,
- Number of Incontinence Episodes; [ Time Frame: Duration of Study ]Number
- Relationship of Incontinence to Urge or Stress [ Time Frame: Duration of study ]4-grade scale
- Psychological Self-reports, Scores on Anxiety and Depression Rating Scales; [ Time Frame: 2 weeks ]State and Trait scores on Spielberger State-Trait Anxiety Inventory; The score measured by the Zung Self-Rating Depression Inventory.
- Quality of Life, Scores on the Women's Health Questionnaire. [ Time Frame: 2 weeks ]Self-reported vasomotor symptoms, other somatic symptoms, anxiety, depression, sleep and cognitive symptoms (memory, concentration and clumsiness problems), measured as category scores. Subjective sleep onset and total sleep times measured as 7-day averaged minutes.
- Sleep Quality [ Time Frame: 2 months ]
- Cognitive Function [ Time Frame: Two 20-minute sessions during 2 months ]Motor speed (number of finger taps in 30 seconds); Continuous Performance (mean response time elicited by appearance of target alphabet letter presented in a series of letters on a monitor screen for 1 minute); Color-Word Stroop Test (response times to stimuli with congruent word and color)
- Hyperarousal [ Time Frame: At baseline and 8 weeks later ]Score on 26-item self-report Hyperarousal Scale that indicates proportion of attention allocated to visceral-somatic information vs. external sensory data.
- Whether She Used Any Pads. [ Time Frame: Duration of Study ]Yes/No
- Pads Used [ Time Frame: Duration of Study ]Pads used
- Sleep / Wake Pattern [ Time Frame: Two weeks ]Wrist actigraphy measures of total daytime and nighttime activity scored by standardized Actiwatch measures of sleep and sake.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00323635
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Brigham & Women's Hospital|
|Boston, Massachusetts, United States, 02120|
|Principal Investigator:||Quentin R Regestein, M.D.||Brigham and Women's Hospital|